Compare Incyte Corporation (INCY) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs MINISO Group Holding Ltd — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while MINISO Group Holding Ltd trades at $12.49 (market cap $3.87B). The key difference: Incyte Corporation is far larger — about 6× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.21% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MNSO | |
|---|---|---|
Market Cap | $23.11B | $3.87B |
Sector | Health | Technology |
52-Week High | $118.52 | $26.63 |
52-Week Low | $67.38 | $11.30 |
Enterprise Value | $19.13B | $4.54B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal driven by moving averages. The stock shows strong fundamentals with a P/E of 12.98 and net income margin of 8.98% for 2026. Recent Q1 2026 earnings beat expectations with EPS of $0.591, and the company announced a HK$2 billion share repurchase program on June 29, 2026, signaling confidence.
Outlook is positive given earnings momentum and valuation support, but risks include margin pressure from overseas expansion costs and mixed quarterly performance. Analyst consensus is 75% buy, though one sell rating highlights growth execution concerns. The stock remains a growth play with manageable valuation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
